For two decades, patients with unresectable liver cancer have faced a narrow corridor of treatment — a looping procedure that buys time but eventually exhausts itself. The EMERALD-3 trial, presented at the 2026 ASCO Annual Meeting, offers the first phase III evidence that pairing immunotherapy with that procedure can meaningfully delay disease progression, extending median progression-free survival from roughly ten months to thirteen. The finding arrives not as a clean answer but as a threshold moment — one that invites medicine to ask not only what works, but for whom, at what cost, and towar
EMERALD-3 Trial Shows STRIDE Plus TACE Improves Outcomes in Unresectable HCC
Patients receiving combination therapy experienced significantly higher rates of serious adverse events (48.6-62.7% grade 3-4 toxicity) with 35-84% requiring treatment interruptions, impacting quality of life and treatment tolerability.